Copyright: ©Author(s) 2026.
World J Nephrol. Mar 25, 2026; 15(1): 114239
Published online Mar 25, 2026. doi: 10.5527/wjn.v15.i1.114239
Published online Mar 25, 2026. doi: 10.5527/wjn.v15.i1.114239
Table 3 Histopathological causes of biopsy proven immune check point inhibitor-related acute kidney injury
| Histopathology | Frequency |
| Acute tubulointerstitial nephritis | |
| Gupta et al[20] (n = 429) | 82.7% |
| Cortazar et al[13] (n = 60) | 93.3% |
| Glomerular diseases | |
| Kitchlu et al[10] (n = 45) | |
| Pauci-immune glomerulonephritis | 26.7% |
| Minimal change disease (with acute tubular injury) | 20.0% |
| C3 glomerulonephritis | 11.1% |
| Immunoglobulin A nephropathy | 8.9% |
| Amyloid A amyloidosis | 8.9% |
| Anti-glomerular basement membrane disease | 6.7% |
| Thrombotic microangiopathy | 4.4% |
| Immune-complex glomerulonephritis | 4.4% |
| Focal segmental glomerulosclerosis | 4.4% |
| Lupus-like nephritis | 2.2% |
| Membranous nephropathy | 2.2% |
- Citation: Javaid MM, Tonkin-Hill G, Klein M. Immune checkpoint inhibitor-related acute kidney injury: A diagnostic and therapeutic challenge for nephrologists. World J Nephrol 2026; 15(1): 114239
- URL: https://www.wjgnet.com/2220-6124/full/v15/i1/114239.htm
- DOI: https://dx.doi.org/10.5527/wjn.v15.i1.114239